Literature DB >> 21920470

Upregulated expression of the PSMB5 gene may contribute to drug resistance in patient with multiple myeloma when treated with bortezomib-based regimen.

Lü Shuqing, Yang Jianmin, Huang Chongmei, Cheng Hui, Jianmin Wang.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21920470     DOI： 10.1016/j.exphem.2011.09.003

Source DB:  PubMed          Journal:  Exp Hematol        ISSN： 0301-472X            Impact factor:   3.084


× No keyword cloud information.
  15 in total

1.  Higher ratio immune versus constitutive proteasome level as novel indicator of sensitivity of pediatric acute leukemia cells to proteasome inhibitors.

Authors:  Denise Niewerth; Niels E Franke; Gerrit Jansen; Yehuda G Assaraf; Johan van Meerloo; Christopher J Kirk; Jeremiah Degenhardt; Janet Anderl; Aaron D Schimmer; Sonja Zweegman; Valerie de Haas; Terzah M Horton; Gertjan J L Kaspers; Jacqueline Cloos
Journal:  Haematologica       Date:  2013-09-20       Impact factor: 9.941

2.  Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes.

Authors:  K Martin Kortüm; Elias K Mai; Nur H Hanafiah; Chang-Xi Shi; Yuan-Xiao Zhu; Laura Bruins; Santiago Barrio; Patrick Jedlowski; Maximilian Merz; Jing Xu; Robert A Stewart; Mindaugas Andrulis; Anna Jauch; Jens Hillengass; Hartmut Goldschmidt; P Leif Bergsagel; Esteban Braggio; A Keith Stewart; Marc S Raab
Journal:  Blood       Date:  2016-07-25       Impact factor: 22.113

3.  Antileukemic activity and mechanism of drug resistance to the marine Salinispora tropica proteasome inhibitor salinosporamide A (Marizomib).

Authors:  Denise Niewerth; Gerrit Jansen; Lesley F V Riethoff; Johan van Meerloo; Andrew J Kale; Bradley S Moore; Yehuda G Assaraf; Janet L Anderl; Sonja Zweegman; Gertjan J L Kaspers; Jacqueline Cloos
Journal:  Mol Pharmacol       Date:  2014-04-15       Impact factor: 4.436

Review 4.  From bortezomib to other inhibitors of the proteasome and beyond.

Authors:  Daniela Buac; Min Shen; Sara Schmitt; Fathima Rani Kona; Rahul Deshmukh; Zhen Zhang; Christine Neslund-Dudas; Bharati Mitra; Q Ping Dou
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

5.  Reversal of bortezomib resistance in myelodysplastic syndrome cells by MAPK inhibitors.

Authors:  Yingxing Yue; Ying Wang; Yang He; Shuting Yang; Zixing Chen; Yuanyuan Wang; Shanshan Xing; Congcong Shen; Hesham M Amin; Depei Wu; Yao-Hua Song
Journal:  PLoS One       Date:  2014-03-07       Impact factor: 3.240

6.  Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines.

Authors:  Denise Niewerth; Gertjan J L Kaspers; Yehuda G Assaraf; Johan van Meerloo; Christopher J Kirk; Janet Anderl; Jonathan L Blank; Peter M van de Ven; Sonja Zweegman; Gerrit Jansen; Jacqueline Cloos
Journal:  J Hematol Oncol       Date:  2014-01-13       Impact factor: 17.388

7.  The resistance mechanisms of proteasome inhibitor bortezomib.

Authors:  Shuqing Lü; Jianmin Wang
Journal:  Biomark Res       Date:  2013-03-01

8.  Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapy.

Authors:  Denise Niewerth; Gertjan J L Kaspers; Gerrit Jansen; Johan van Meerloo; Sonja Zweegman; Gaye Jenkins; James A Whitlock; Stephen P Hunger; Xiaomin Lu; Todd A Alonzo; Peter M van de Ven; Terzah M Horton; Jacqueline Cloos
Journal:  J Hematol Oncol       Date:  2016-09-06       Impact factor: 17.388

9.  Proteasomal adaptations to FDA-approved proteasome inhibitors: a potential mechanism for drug resistance?

Authors:  Kyung Bo Kim
Journal:  Cancer Drug Resist       Date:  2021-05-30

Review 10.  (Immuno)proteasomes as therapeutic target in acute leukemia.

Authors:  Jacqueline Cloos; Margot Sf Roeten; Niels E Franke; Johan van Meerloo; Sonja Zweegman; Gertjan Jl Kaspers; Gerrit Jansen
Journal:  Cancer Metastasis Rev       Date:  2017-12       Impact factor: 9.264
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.